Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Tiziana joins type 1 diabetes prevention field

Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.

Latest news

Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in DLBCL and follicular lymphoma, and moving the ADC into earlier lines of therapy.
Type 1 diabetes prevention promise sends Provention Bio soaring

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
Regeneron's bispecific for lymphoma works in CAR-T failures

The new data for the highly-touted bispecific antibody – which targets both CD20 and CD3 – was presented at the European Haematology Association (EHA) congress in Amsterdam and showed very high response ... REGN1979 is in a race to market with a
So far so good for Amgen's much-anticipated KRAS inhibitor

Clinical data will be available on two new BiTEs, an anti-BCMA and CD3 candidate AMG 420 for relapsed/refractory multiple myeloma – which was a highlight of the ASH programme last ... December – and pasotuxizumab, a PSMA and CD3-targeting BiTE for
Xencor’s Novartis-partnered bispecific on hold after patient deaths

CD3 is a popular domain target for bispecific antibodies as it activates T-cells to kill malignant cells. ... It’s not the first CD3-targeting bispecific to run into safety concerns.

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during February 2014

CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director, Healthcare Communications: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Empowered patients: shaking the foundations of healthcare: Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....